Research ArticleALS

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

See allHide authors and affiliations

Science Translational Medicine  05 Dec 2018:
Vol. 10, Issue 470, eaah3924
DOI: 10.1126/scitranslmed.aah3924

Article Information

vol. 10 no. 470

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication November 8, 2016
  • Resubmitted December 15, 2017
  • Accepted for publication May 16, 2018

Author Information

  1. Marcel Maier1,*,
  2. Tobias Welt2,*,
  3. Fabian Wirth1,
  4. Fabio Montrasio1,
  5. Daniel Preisig2,
  6. Jordan McAfoose2,
  7. Fernando G. Vieira3,
  8. Luka Kulic2,
  9. Claudia Späni2,
  10. Thilo Stehle4,
  11. Steve Perrin3,
  12. Markus Weber5,
  13. Christoph Hock1,2,
  14. Roger M. Nitsch1,2 and
  15. Jan Grimm1,
  1. 1Neurimmune AG, 8952 Schlieren, Switzerland.
  2. 2Institute for Regenerative Medicine–IREM, University of Zurich, 8952 Schlieren, Switzerland.
  3. 3ALS Therapy Development Institute, Cambridge, MA 02139, USA.
  4. 4Interfaculty Institute of Biochemistry, University of Tübingen, 72076 Tübingen, Germany.
  5. 5Muskelzentrum/ALS Clinic, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
  1. Corresponding author. Email: jan.grimm{at}neurimmune.com
  • * These authors contributed equally to this work.

Altmetric

Article usage

Article usage: December 2018 to December 2018

AbstractFullPdf
Dec 201877711659585